Although we observed a significant increase in ERK1/2 in palbociclib-sensitive tumours (compared to vehicle), this could be a compensatory mechanism to overcome cell cycle arrest; however, since the CDK4/6 pathway is downstream of this, palbociclib still exerts its inhibitory effect. Here, CDK4 is linked to neoplasm.